ChromaDex (NASDAQ:CDXC) Lowered to "Buy" Rating by StockNews.com

ChromaDex (NASDAQ:CDXC - Get Free Report) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a note issued to investors on Tuesday.

Several other equities research analysts also recently issued reports on CDXC. HC Wainwright raised their price target on ChromaDex from $6.00 to $8.00 and gave the company a "buy" rating in a report on Monday, November 4th. Roth Mkm upped their target price on ChromaDex from $6.00 to $8.00 and gave the company a "buy" rating in a research report on Wednesday, November 6th.

ChromaDex Trading Down 2.4 %

Shares of ChromaDex stock traded down $0.15 during trading on Tuesday, hitting $6.00. 662,205 shares of the stock were exchanged, compared to its average volume of 550,714. The company has a fifty day moving average price of $5.71 and a 200-day moving average price of $4.01. The stock has a market capitalization of $458.30 million, a price-to-earnings ratio of 592.00 and a beta of 2.16. ChromaDex has a 1-year low of $1.34 and a 1-year high of $7.97.

ChromaDex (NASDAQ:CDXC - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. The firm had revenue of $25.58 million for the quarter, compared to the consensus estimate of $23.70 million. During the same quarter in the previous year, the business earned ($0.01) earnings per share. Equities research analysts forecast that ChromaDex will post 0.04 EPS for the current fiscal year.

Insider Activity at ChromaDex

In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of ChromaDex stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $6.19, for a total value of $230,026.59. Following the completion of the sale, the director now directly owns 244,179 shares in the company, valued at approximately $1,511,468.01. The trade was a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 9.64% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On ChromaDex

Hedge funds have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company acquired a new stake in shares of ChromaDex during the 2nd quarter worth $31,000. Merriman Wealth Management LLC acquired a new stake in ChromaDex during the second quarter worth about $32,000. FMR LLC bought a new position in ChromaDex in the 3rd quarter valued at about $55,000. Marshall Wace LLP bought a new position in ChromaDex in the 2nd quarter valued at about $56,000. Finally, SG Americas Securities LLC acquired a new position in shares of ChromaDex in the 3rd quarter valued at approximately $61,000. Institutional investors own 15.41% of the company's stock.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.